Physicians' Academy for Cardiovascular Education

CV outcomes with medicines to control glycemia: highlights from recently completed trials

3' education - Feb. 2, 2016 - VBWG, Orlando - Darren K. McGuire, MD

Video navigation menu

  • Altered rules for the development of diabetes drugs 0:02
  • Data of 5 CV outcomes trials have now been published 0:46
  • CV neutrality in trials testing DPP4-inhibitors vs. placebo 0:59
  • Also adequate CV safety with GLP-1 receptor agonist 1:23
  • Superiority for CV outcomes with a new class of antidiabetic treatment: the SGLT2-antagonist 1:47

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: